Mirati fires its CEO

Mirati Shakes Up Leadership and Lung Cancer Trial Plan

Mirati fires its CEO and announces a new lung cancer Krazati-Keytruda study strategy

SG Tylor

Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...